{rfName}
Al

Indexed in

License and use

Altmetrics

Analysis of institutional authors

Duran-Güell MAuthorFlores-Costa RAuthorCasulleras MAuthorLópez-Vicario CAuthorTitos EAuthorDiaz AAuthorAlcaraz-Quiles JAuthorFernandez JAuthorArroyo VAuthorClaria JCorresponding Author

Share

February 7, 2021
Publications
>
Article
No

Albumin protects the liver from tumor necrosis factor α-induced immunopathology

Publicated to:Faseb Journal. 35 (2): e21365- - 2021-02-01 35(2), DOI: 10.1096/fj.202001615rrr

Authors: Duran-Güell, M; Flores-Costa, R; Casulleras, M; López-Vicario, C; Fernández, J; Arroyo, V; Clària, J; Titos, E; Alcaraz-Quiles, J; Díaz, A; Horrillo, R; Costa, M

Affiliations

Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas - Author
European Foundation for the Study of Chronic Liver Failure (EF-CLIF) - Author
Grifols Bioscience Research Group - Author
Hospital Clinic Barcelona - Author
Universitat de Barcelona - Author
‎ CIBERehd, Biochem & Mol Genet Serv, Hosp Clin IDIBAPS, Barcelona, Spain - Author
‎ European Fdn Study Chron Liver Failure EF Clif &, Barcelona, Spain - Author
‎ Grifols, Biosci Res Grp, Barcelona, Spain - Author
‎ Hosp Clin Barcelona, Liver Unit, Barcelona, Spain - Author
‎ Hosp Clin Barcelona, Pathol Serv, Barcelona, Spain - Author
‎ Univ Barcelona, Dept Biomed Sci, Barcelona, Spain - Author
See more

Abstract

© 2021 Federation of American Societies for Experimental Biology. Besides its oncotic power, albumin exerts pleiotropic actions, including binding, transport, and detoxification of endogenous and exogenous molecules, antioxidant activity, and modulation of immune and inflammatory responses. In particular, recent studies have demonstrated that albumin reduces leukocyte cytokine production. Here, we investigated whether albumin also has the ability to protect tissues from the damaging actions of these inflammatory mediators. We circumscribed our investigation to tumor necrosis factor (TNF) α, which exemplifies the connection between immunity and tissue injury. In vivo experiments in analbuminemic mice showed that these mice exhibit a more pronounced response to a model of TNFα-mediated liver injury induced by the administration of lipopolysaccharide (LPS) and D-galactosamine (D-gal). A tissue protective action against LPS/D-gal liver injury was also observed during the administration of human albumin to humanized mice expressing the human genes for albumin and neonatal Fc receptor (hAlb+/+ /hFcRn+/+ ) with preestablished carbon tetrachloride (CCl4 )-induced early cirrhosis. The cytoprotective actions of albumin against TNFα-induced injury were confirmed ex vivo, in precision-cut liver slices, and in vitro, in primary hepatocytes in culture. Albumin protective actions were independent of its scavenging properties and were reproduced by recombinant human albumin expressed in Oryza sativa. Albumin cytoprotection against TNFα injury was related to inhibition of lysosomal cathepsin B leakage accompanied by reductions in mitochondrial cytochrome c release and caspase-3 activity. These data provide evidence that in addition to reducing cytokines, the albumin molecule also has the ability to protect tissues against inflammatory injury.

Keywords

cytokine&#8208hepatocyte apoptosisinduced tissue injuryliver cellsliver injurymicemitochondrial damagemitochondrial releasemodelpathwayreceptorAlbuminCytokine&#8208Cytokine-induced tissue injuryHepatocyte apoptosisHuman serum-albuminInduced tissue injuryLiver cellsLiver injuryMiceMitochondrial damageMitochondrial releaseModelPathwayReceptor

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Faseb Journal due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2021, it was in position 16/94, thus managing to position itself as a Q1 (Primer Cuartil), in the category Biology.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 1.19. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 1.28 (source consulted: FECYT Feb 2024)
  • Field Citation Ratio (FCR) from Dimensions: 7.36 (source consulted: Dimensions Aug 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-08-29, the following number of citations:

  • WoS: 23
  • Scopus: 23
  • Europe PMC: 3

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-08-29:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 28 (PlumX).

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Duran Güell, Marta) and Last Author (Claria Enrich, Joan).

the author responsible for correspondence tasks has been Claria Enrich, Joan.